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Introduction
Our original proposal was based on preliminary data suggesting that estrogen receptor alpha (ER) is present in a complex with the small scaffold protein Mek Partner-1 (MP1) in human breast cancer cell lines, and that overexpression of MP1 via transient transfection increases ER's transcriptional activity. Based on this, we proposed that MP1 would be required for proliferation of ER-positive breast cancer cells, and that understanding the ER/MP1 complex would give insights into the mechanism by which it was acting. MP1 is a widely expressed scaffold protein that interacts with several intracellular kinases that are known to impact ER function, including MEK, ERK and PAK1. It was first identified as a protein that binds to ERK and MEK, and that potentiates MAPK signaling [1] . It also binds to active PAK1 at the plasma membrane, and integrates PAK1 and Rho signaling [2] . Knockdown of MP1 inhibits spreading of fibroblasts on fibronectin [2] , and also results in decreased migration of human prostate cancer epithelial cells on fibronectin [3] . Surprisingly, neither ERK nor PAK1 phosphorylation was dramatically altered when MP1 expression was inhibited in prostate cancer epithelial cells. However, the decreased migration observed upon MP1 knockdown was correlated with decreased paxillin expression and with changes in the number and turnover of focal adhesions at the migratory edge. Thus, one function of MP1 is related to cell attachment, spreading and migration.
In this research project, we investigated the function of MP1 in human breast cancer cell lines. The original aims of our proposal were 1: To test the hypothesis that MP1 is required for ER function and proliferation in human breast cancer cells, and 2: To characterize the subcellular localization and protein composition of ER/MP1 complexes. In our previous annual reports, we described our unsuccessful efforts to reproduce the initial coimmunoprecipitation experiments demonstrating the existence of a stable complex containing both ER and MP1. Due to this, we have been unable to carry out the experiments described in Aim 2, and have concentrated our efforts on Aim 1. Many of the findings from this aim have been described in our previous annual reports, and are shown in the manuscript that is included here as Appendix 3. They can be briefly summarized as follows. 1) Inhibition of MP1 expression by RNA interference results in cell detachment and apoptosis of ER-positive breast cancer cell lines, but not ER-negative breast cancer cell lines or non-tumorigenic mammary epithelial cell lines. 2) MP1 gene silencing in ER-positive cell lines is associated with an approximate 2-3 fold decrease in ER expression and transcriptional activity, and with an approximate 2 fold decrease in the active, phosphorylated form of AKT. In agreement with the findings in prostate cancer cells, MP1 silencing does not result in decreased ERK activity in ERpositive breast cancer cells. 3) Overexpression of MP1 in ER-positive breast cancer cell lines results in increased cell migration and invasion.
For the past year, we have concentrated our efforts on determining if decreased ER and/or AKT activity is responsible for the apoptosis observed upon MP1 gene silencing. Our progress in these experiments is reported below and in the accompanying manuscript (Appendix 3).
Body: Progress on Each Task in Approved Statement of Work.

Task 1: Test hypothesis that MP1 expression is required for ER's transcriptional activity and proliferation of human breast cancer cells.
As we reported previously, both total ER and phosphorylated AKT levels decrease within 48 h of MP1 knockdown in MCF-7 cells (A ppendix 3, Figures 5B and 5D ). To determine if decreased ER levels are responsible for th e apoptosis observed, th e effects of silencing the ER gene alone or in combination with the MP1 gene were examined. Silencing of ER did not result in apoptosis of MCF-7 c ells, indicating that decreased ER expr ession alone is not the cause of apoptosis in MP1 siRNA trea ted cells (Appendix 3, Figu re 5C). In addition silencing ER did not p revent apoptosis induced by MP1 silencing (Appendix 3, Fi gure 5C), suggesting that ER expression is not required for the apoptotic response.
Inhibition of MP1 expression resulted in cell deat h in MCF-7 cells, and this was correlated with a decrease in the pho sphorylated (active) form of AKT1 (Appendix 3, Figure 5D ). In contrast , MDA-MB-231 cells showed no increase in cell death in response to MP1 knockdown (Appendix 3, Figures 3 and 4) . If decrease d AKT activity was responsible fo r the cell death observed after MP1 knockdown in MCF-7 cells, the lack of deat h in MDA-MB-231 cells could be due to the fact that AKT activity is not dependent on MP1 in MDA-MB-231 cells, or that survival of these cells is not dependent upon active AKT. To test the latter possibility, MCF-7 and MDA-MB-231 cells were treated with various concentrations of the PI3K inhibito r LY294002, and the effects on AKT1 phosphorylation and cell viability were examined. As shown in Appendix 3 Figure 6A , a concentration of 20 µM was sufficient to partially inhibit PI3K activity in both cell lines. MCF-7 cell viability declin ed upon LY294002 treatment (A ppendix 3, Figure 6B ), and this was the result of ap optosis as indicated by increased PARP cleavage (Appendi x 3, Figure 6C ). In contrast, MDA-MB-231 cell viab ility was un affected by LY294002 treatm ent. These data indicate that MCF-7 cells are m ore dependent on pro-survival signaling from PI3K/AKT1 than MDA-MB-231 cells, and are in agreem ent with previous reports s howing a differential requirement for PI3K signaling in these two cell lines (4, 5) .
Since MP1 silencing resulted in decreased AKT activity in MCF-7 cells, and since these cells are highly dependent on pro-survival signals from the PI3K/AKT pathway, we hypothesized that MCF-7 cells containing a constitutively active form of AKT1 would not undergo apoptosis in response to MP1 silencing. To test this hypothesi s, we generated pools of stably transfected MCF-7 cells expressing constitutively activ e AKT1 (MCF-7/Myr-Flag-AKT1). Phosphorylated-AKT1 (p-AKT) was highly expressed in a pool of MCF-7/Myr-Flag-AKT1 cells compared to a pool of cells containing the control pBabe-puro vector (Appendix 3, Figure 7A ). These two pools of cells were transfected with MP1 siRNA or c ontrol siRNA, and th e effects on cell su rvival were examined. As shown in Appendix 3 Figure 7B , 64% of vector containing cells were dead in the MP1 s iRNA treated sam ple, but this decreased to 41% in c ells expressing constitutively active AKT1. In addition, the exte nt of PARP cleavage in re sponse to MP1 silencing was decreased in Myr-Flag -AKT1 expressing cells re lative to the contro l cell line (Appendix 3, Figure 7C ). These experiments were repeated with clonal transfectants containing control vector or Myr-Flag-AKT1 with similar results (data not shown). Together, these findings indicate that expression of active AKT1 partiall y overcomes the requirement for MP1 expression for survival 6 of MCF-7 cells, and suggests that the apoptosis observe d upon MP1 silencing is due, at least in part, to a loss of pro-survival signaling from the AKT pathway. Tasks 2-4: As described above and in previous repor ts, we have been unable to reproduce our initial co-IP experiments. Since tas ks 2-4 a ll depending on isolating ER/MP1 complexes, we could not carry out the experiments described in these tasks.
Key Research Accomplishments (entire grant period):
 Demonstrated that MP1 expression is required for survival of ER-positive breast cancer cell lines, but not ER-negative breast cancer cell lines or non-tumorigenic mammary epithelial cell lines.
 Demonstrated that silencing the MP1 gene results in decreased ER expression and activity in MCF-7 cells. However, a loss of ER function does not seem to be the cause of cell death, since no significant increase in apoptosis is observed when the ER gene itself is silenced.
 Demonstrated that silencing the MP1 gene leads to decreased AKT phosphorylation, and that expression of constitutively active AKT1 partially rescues cells from apoptosis induced by MP1 silencing. This suggests that the apoptosis observed upon MP1 gene silencing is due, at least in part, to a loss of pro-survival signaling through AKT. 
Conclusions:
Our experiments have revealed a novel requirement for MP1 expression for the survival of ERpositive breast cancer cells. The pro-survival functions of MP1 seem to be mediated, at least in part, via AKT. MP1 has previously been shown to interact with a number of signaling molecules including ERK, MEK and PAK1, and to play a role in cell attachment and migration. However, the facts that it is required for optimal AKT activity and for cell survival are both novel findings, and suggest that its role in cell survival may be specific to a limited number of cell types, including ER-positive breast cancer cells.
The requirement for MP1 expression in ER-positive breast cancer cells suggests that this small scaffold protein may provide a novel target for the treatment of ER-positive breast tumors. The current targeted therapies for ER-positive tumors (antiestrogens and aromatase inhibitors) have been very effective, but the occurrence of both de novo and acquired resistance is an important clinical problem that limits their efficacy. Our results indicate that cells with acquired antiestrogen resistance (LCC9) retain dependence on MP1, suggesting that agents targeting this scaffold protein could be used to treat endocrine resistant tumors. In addition, the availability of agents targeting two different molecules (ER and MP1) in ER-positive breast cancer cells would offer the opportunity to use them in combination with each other. Since the probability of a single cell acquiring simultaneous resistance to two agents would likely be much lower than to a single agent alone, combination therapy could decrease the frequency of treatment failure and relapse. Since ER-positive tumors are the most common form of breast cancer, and since endocrine resistance is a significant cause of disease relapse and death, this work has the potential to impact a large number of breast cancer patients. To test th is hypothesis, we used tran sient transfection with siRNA to investigate th e function of MP1 in a panel of hum an mammary epithelial cell line s that includes n on-tumorigenic, ER-positive and ERnegative breast cancer cell lin es. After 48 hours, ER-positiv e cell lines tran sfected with MP1siRNA (but not control siR NA) rounded up and detached fr om the plate, and trypan blue staining indicated the majority of MP1siRNA treated cells were dead. No significant increase in cell detachment or death was observed in ER-neg ative cells treated with MP1 siRNA relative to con trol siRNA, although im munoblotting confirmed that MP1 p rotein levels were successf ully reduced in all cell lines. The phenotype observed when MP1 expression was inhibited in ER-positive cells was further characterized using the MCF-7 cell model. Inhibition of MP1 expression in this cell line resulted in cleavage of PARP-1, and both this cleavage and the cell rounding/detachment phenotype could be rescued with the pan-caspase inhibitor z-VAD-FMK. W e therefore conclude that inhibition of MP1 expression induces apoptosis in MCF-7 cells. Additional experiments were carried out to identify pro-survival pathways that are re gulated by MP1 in MCF-7 cells. Inhibition of MP1 expression resulted in d ecreased expression of ER, in tegrin beta 1, and phosphor-AKT1. Direct inhibition of ER expression wi th ER siRNA did not result in cell de ath, making this an unlikely mechanism of cell de ath. However, MCF-7 cells were shown to be very dependent on P I3K signaling, and the cell death phenotype was partially rescued by expression of constitutively active AKT1. Thes e results suggest that the inhibition of MP1 expression results in a loss of pro-survival signaling fr om integrin beta-1 and/or PI3K-AKT pathways, and that MP1 expression is required specifically for survival of ER-positive, but not ER-negative, breast cancer cells. Approximately 70% of breast tumors express estrogen receptor (ER), and the majority of these require estrogen for proliferation and/or survival. Many functions of the ER rely on cross-talk with cellular signaling molecules, including ERK, PAK1, and AKT1. These intracellular kinases can all phosphorylate ER, and the resulting phosphorylation events may alter ER activity and/or ligand dependence. In addition, ER can affect the activity of intracellular kinases via protein-protein interaction, indicating that the cross talk between ER and intracellular kinases is bidirectional. Understanding the molecular basis and functional consequences of this cross talk is important in order to understand ER's role in breast cancer. MEK Partner 1 (MP1, also known as Map Kinase Scaffold Protein 1 or MAPKSP1) is a widely expressed scaffold protein that interacts with several protein kinases that impact ER function and breast cancer biology, including ERK1 and PAK1. We investigated the role of MP1 in breast cancer cells using both RNA interference and overexpression approaches. To study the effects of inhibiting MP1 expression, a panel of human mammary epithelial cell lines that included non-tumorigenic cells, ER-positive breast cancer cells and ER-negative breast cancer cells were transiently transfected with MP1 siRNA or control siRNA. Within 48 hours, up to 80% of ER-positive breast cancer cells transfected with MP1siRNA rounded up and detached from the plate, and trypan blue staining indicated that the majority of detached cells were dead. No significant increase in cell detachment or cell death was observed in ER-negative breast cancer cells or non-tumorigenic cells as a result of inhibiting MP1 expression. The mechanism of cell death in ER-positive breast cancer cells was characterized using the MCF-7 cell line. Increased PARP-1 protein cleavage was detected in MP1 siRNA-treated MCF-7 cells. Both PARP cleavage and cell detachment/death were prevented by pre-treatment with the pan-caspase inhibitor z-VAD-FMK, indicating an apoptotic mechanism of death. Inhibition of MP1 expression in MCF-7 cells also resulted in decreased levels of ER and p-AKT, suggesting a loss of pro-survival signaling from the ER and/or PI3K-AKT pathways. The effect of overexpressing MP1 in MCF-7 cells was investigated using transient and stable transfection of Flag-MP1 constructs. Overexpression of MP1 led to an increase in both cell migration and invasion in Boyden chamber assays. In summary, our experiments suggest that MP1 expression is required for survival of ER-positive, but not ER-negative breast cancer cells, and may also play a role in migration and invasion of ER-positive cells. Previous studies in fibroblasts and prostate cancer cells identified roles for MP1 in focal adhesion turnover, and in cell attachment, spreading and migration. A role in cell survival has not been previously reported, and may be specific to ER-positive breast cancer cells. Our current experiments are directed towards identifying the signaling pathways affected by MP1 in ER-positive breast cancer cells, and evaluating the potential of these pathways as targets to inhibit cell survival and/or migration.
MP1 IS REQUIRED FOR SURVIVAL OF ER-POSITIVE BREAST CANCER CELLS
INTRODUCTION
The small protein MEK Partner 1 (MP1, also known as Map Kinase Scaffold Protein 1 and LAMTOR3) was originally identified as a scaffold protein that potentiates MAPK signaling by binding to MEK1 and ERK1 (1) . MP1 interacts with another small protein p14, and together these two proteins are localized to endomembrane compartments as part of larger signaling complexes. For example, an MP1-p14-MEK1 complex is localized to late endosomes, and this localization is required for EGF-induced ERK1/2 signaling (2-4). A second MP1-p14-p18
Ragulator complex is required for the recruitment of mTORC1 to the lysosomal surface, and is essential for its amino acid-dependent signaling (5) . In addition to these trimeric complexes, MP1 has been reported to bind PAK1 at the plasma membrane, and the MP1-PAK1 interaction is required for MEK phosphorylation by PAK1 in the absence of Raf (6, 7 with 5% fetal bovine serum (HyClone), and 100 Units/ml Penicillin/100 µg/ml Streptomycin (Invitrogen) and incubated at 37 ºC with 5% CO 2 . 
Retroviral infection of MCF-7 cells. pBabe-puro (Addgene plasmid 1764) or pBabe-puro-Myr-
Flag-AKT1 (Addgene plasmid 15294, (10)) were transfected into 293GPG packaging cells and retroviral stocks were prepared as previously described (11) . These virus stocks were used to infect MCF-7 cells (1 ml per 10 cm dish), in the presence of polybrene (8 µg/ml), and stable colonies were selected with 0.5 µg/ml puromycin. Both single colonies and pools of 50-100 colonies were selected and propagated. Stable cell lines/pools were routinely maintained in medium supplemented with 0.25 µg/ml puromycin and plated in puromycin-free conditions for siRNA transfections.
Gene expression analysis. To examine gene expression across human breast cancer, datasets
were downloaded from GEO including: GSE2034, GSE3494, GSE6532, GSE4922, GSE11121, GSE7390, GSE2603 and GSE14020. Data was normalized using RMA in Affymetrix Expression However, our analysis did not reveal a correlation between high MP1 expression and either time to distant metastasis or disease free survival.
RESULTS
MP1 expression profiling in human mammary epithelial cells.
Expression of MP1 protein was assessed by immunoblotting in the following
Inhibition of MP1 expression induces cell death and detachment of ER-positive breast cancer cells.
To study the effect of inhibiting MP1 expression in breast cancer cells, short interfering is an independently derived ER-positive cell line. MP1 siRNA #1 was used in these experiments. As shown in Figure 2C , LCC9 and T47D cells exhibited a similar phenotype to MCF-7. To quantitate the effect of MP1 knockdown, attached and detached cells were collected at 48 h following siRNA transfection, stained with trypan blue, and counted. As shown in Figure   2E , MCF-7 cells were the most sensitive to MP1 knockdown. More than 70% of cells had detached by 48 h, and the majority of these were dead as determined by trypan blue staining. In contrast, only 10% of cells were detached in the control siRNA transfections. Although LCC9 9 and T47D cells were less sensitive than MCF-7, both showed a significant increase in dead/floating cells upon MP1 knockdown, with the average percentage of dead cells being 70%
for MCF-7, 42% for LCC9 and 49% for T47D ( Figure 2D ).
Inhibition of MP1 expression does not induce death of ER-negative breast cancer cells or nontumorigenic cells.
Since MP1 is expressed in ER-negative breast cancer cells and in non-tumorigenic mammary epithelial cells (Figure 1 ), the effects of MP1 knockdown in representatives of these cell types were also examined. Three ER-negative breast cancer cell lines (MDA-MB-231, BT-549, and Sk-Br-3) and one non-tumorigenic mammary epithelial cell line (184B5) (14) were transfected with either control or MP1 siRNA and examined at 48 h. Although MP1 levels were decreased to the same or greater extent than that obtained in the ER-positive lines, no obvious changes in cell morphology were seen, and cell counting/trypan blue exclusion indicated that there was no significant increase in cell detachment or death in MP1 siRNA transfected cells compared with control samples (Figure 3) . Thus, the requirement for MP1 expression for cell attachment and survival may be specific to ER-positive breast cancer cells.
Inhibition of MP1 expression results in apoptosis of MCF-7 cells.
To determine if the cell death observed in MCF-7 cells upon MP1 silencing was due to apoptosis, expression of the anti-apoptotic protein Bcl-2 was examined. As shown in Figure 4A 
MP1 knockdown reduces ER protein expression and decreases AKT activity but does not impact ERK expression or activity in MCF-7 cells.
To identify pathways affected by MP1 knockdown, expression of ER and of total and phosphorylated ERK and AKT1 were examined ( Figure 5 ). AKT1 is a pro-survival protein with a well-established role in the biology of cancer. Both ER and ERK are typically associated with proliferation, but may also be involved in regulating cell survival. The level of phospho-ERK was unaffected by MP1 knockdown (Figure 5A ), suggesting that a loss of ERK signaling is not responsible for the cell detachment and death observed. In contrast, both total ER and phosphor-AKT levels decreased within 48 h of MP1 knockdown ( Figure 5B and 5D ). To determine if decreased ER levels were responsible for the apoptosis observed, the effects of silencing the ER gene alone or in combination with the MP1 gene were examined. Silencing of ER did not result in apoptosis of MCF-7 cells, indicating that decreased ER expression alone is not the cause of apoptosis in MP1 siRNA treated cells ( Figure 5C ). In addition silencing ER did not prevent apoptosis induced by MP1 silencing ( Figure 5C ), suggesting that ER expression itself is not required for the apoptotic response.
Differential requirement for PI3K/AKT pathway for survival of MCF-7 and MDA-MB-231 cells.
Inhibition of MP1 expression resulted in cell death in MCF-7 cells, and this was correlated with decreased phosphorylated (active) AKT1 ( Figure 5D ). In contrast, MDA-MB- 
Constitutively active AKT1 partially rescues MP1 siRNA induced apoptosis of MCF-7 cells.
MP1 knockdown was correlated with decreased activation of AKT1 in MCF-7 cells, which are highly dependent on pro-survival signals from the PI3K/AKT pathway. To examine whether active AKT1 is sufficient to maintain cell viability in the absence of MP1, we generated MCF-7 cells expressing constitutively active AKT1 (MCF-7/Myr-Flag-AKT1). Phosphorylated-AKT1 (p-AKT) was highly expressed in a pool of MCF-7/Myr-Flag-AKT1 cells compared to a pool of cells containing the control pBabe-puro vector ( Figure 7A ). These two pools of cells were transfected with MP1 siRNA or control siRNA, and the effects on cell survival were examined. As shown in Figure 7B , 64% of pBabe-puro containing cells were dead in the MP1 siRNA treated sample, but this decreased to 41% in cells expressing constitutively active AKT1.
In addition, the extent of PARP cleavage in response to MP1 silencing was decreased in MyrFlag-AKT1 expressing cells relative to the control cell line ( Figure 7C ). These experiments were repeated with clonal transfectants containing control vector or Myr-Flag-AKT1 with similar results (Supplementary Figure 1) . Together, these findings indicate that expression of active AKT1 partially overcomes the requirement for MP1 expression for survival of MCF-7 cells.
DISCUSSION
The results presented here reveal a novel role for the small scaffold protein MP1 in ERpositive breast cancer cells. Although MP1 is expressed in both ER-positive and ER-negative breast cancer cells, its depletion using RNAi-mediated gene silencing led to detachment and death of several ER-positive cell lines, including one (LCC9) with acquired estrogen independence and antiestrogen resistance. In contrast, MP1 gene silencing had no detectable effect in three ER-negative breast cancer cell lines or a non-tumorigenic mammary epithelial cell line. Although this is a limited sample, MP1 has also been depleted in rat fibroblasts and human prostate cancer cells, and cell detachment or death was not reported in either case (7, 8) . 
